Tropical Doctor, April 1998 responsibilities to educate our politicians as to the benefits of sharing communicable disease data at an international level.
There is a growing need for the medical practitioner who is challenged by the kaleidoscope of infectious diseases and gains satisfaction from studying them at the level of the whole organismhis or her patientsrather than at the level of a nucleotide. This is not a call for dilettante 'stamp collectors' to simply record new or changing diseases, but for those who feel an obligation to present and future generations to try to understand, and perhaps to challenge, those infectious diseases which are genuinely emerging or re-emerging. . Some of the problems are similar to those found in the Western world, namely that epilepsy is a chronic disease requiring long-term medication, others to beliefs prevalent in certain countries about the nature and cause of the condition, and yet others to the shortage of medical resources available. Among the difficulties encountered are: (a) the need to ensure an ongoing supply of medication (particularly in view of the risk of withdrawal seizures from the abrupt cessation of phenobarbitone, widely used in these countries because it is the least expensive antiepileptic drug); (b) the cost of the drugs themselves; (c) the fact that, in contrast to the drugs used for the more familiar acute diseases, treatment must be continued even when the patient is apparently well; and (6) beliefs relating to causation, which may mean that consulting a traditional healer is viewed as more relevant than the use of conventional drugs. As noted by the authors, the 'treatment gap' -a measure of the proportion of patients with the condition yet remaining untreatedhas been estimated at more than 80%'. posts by the patients and their families is an important aspect of the scheme, and implies a commitment on their part to its working successfully. The involvement of more conventional personnel appears to be largely in a training and supervisory role. Obviously, there are aspects of the project which would not be viewed as ideal in many Western countries. Relatively few patients became entirely seizure-free compared with the accepted figure of 60-70% of patients achieving complete seizure control when started on medication2. This may be, in part, due to the fact that these were people identified in a prevalence survey. Some of them, therefore, would already have had epilepsy for a considerable length of time and hence would, by definition, have relatively refractory epilepsy. However, it seems likely that the fixed drug dosages used (presumably on account of infrequent medical contact, together with a lack of drug level monitoring) provided some patients with a sub-optimal dose of phenobarbitone. The lack of ongoing medical contact also means that patients' concerns regarding their drug treatment could not easily be answered. Nevertheless, in a situation in which the alternative might be no drug treatment at all, the improvements achieved represent a considerable advance.
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The early results from the study are promising. However, as noted above, regardless of whether the patient lives in a developing country or in the Western world, compliance in epilepsy is often poor, and the proof of the long-term effectiveness of the system described will only be evident from further follow-up. 
YVONNE HART

